Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. Articles
  3. preclinical efficacy data
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Videos

Refine by
Date

  • Older

Preclinical Efficacy Data Articles & Analysis

8 articles found

From Inflammation to Cancer: How Chemokines Shape Modern Medicine

From Inflammation to Cancer: How Chemokines Shape Modern Medicine

By administering recombinant chemokines, scientists can redirect immune cells to the tumor microenvironment, potentially enhancing the efficacy of checkpoint inhibitors or CAR-T cell therapies. For instance, CXCL10 has shown promise in preclinical models by enhancing T-cell infiltration into tumors. ...

ByCreative BioMart


An Emerging Aim: ADC Target Protein - Nectin-4

An Emerging Aim: ADC Target Protein - Nectin-4

The biologics license application (BLA) has been accepted for Enfortumab Vedotin for the treatment of locally advanced or metastatic urothelial carcinoma in patients who have previously received PD-1/PD-L1 inhibitors and platinum-containing chemotherapy. Enfortumab Vedotin is the first domestically submitted targeted antibody-drug conjugate that specifically targets Nectin-4. Enfortumab ...

ByBeta Lifescience


The Toxicity Atlas - One year later

The Toxicity Atlas - One year later

It’s been about a year since I started my PhD project named The Toxicity Atlas. In this four-year project, I’m collaborating with researchers from Amsterdam UMC and my colleagues at Medstone to find better treatment options for patients with brain cancer. Let me tell you more about my results so far. Information databases Developing new drugs costs a lot of money and a lot of ...

ByMedstone Holding BV


A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

AFM13 is a first-in-class tetravalent, bispecific NK cell engager that binds to CD30 on tumor cells and CD16A on NK cells. By engaging CD16-positive NK cells, AFM13 leads to NK cell-mediated killing of tumor cells.1 Pembrolizumab (Keytruda®) is approved in patients with R/R classical Hodgkin lymphoma as monotherapy. AFM13 showed single agent clinical activity with solid safety profile in a ...

ByAffimed GmbH


Rani developing technology for oral delivery of injectable biologics

Rani developing technology for oral delivery of injectable biologics

(NASDAQ:RANI) is developing a disruptive technology to solve the problem of converting biologic injectable drugs, including antibodies, peptides and proteins, into oral therapies with its RaniPill that bypasses destruction in the stomach to deliver its payload to the vascular intestinal wall in the GI tract. “This is not a new idea, although previous attempts were based on chemistry and ...

ByRani Therapeutics


Treos Bio Announces the Publication of Preclinical Data in Frontiers in Genetics Showing its COVID-19 Peptide Vaccine Mimics the Diversity of T Cell Immunity Produced by Natural SARS-CoV-2 Infection

Treos Bio Announces the Publication of Preclinical Data in Frontiers in Genetics Showing its COVID-19 Peptide Vaccine Mimics the Diversity of T Cell Immunity Produced by Natural SARS-CoV-2 Infection

LONDON, June 28, 2021 (GLOBE NEWSWIRE) – Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies, today announced the publication of a peer-reviewed article titled “A Peptide Vaccine Candidate Tailored to Individuals’ Genetics ...

ByTreos Bio Limited


A hybrid modeling approach for assessing mechanistic models of small molecule partitioning in vivo using a machine learning integrated modeling platform

A hybrid modeling approach for assessing mechanistic models of small molecule partitioning in vivo using a machine learning integrated modeling platform

Pharmacokinetic (PK) predictions of compound disposition are critical for safety and efficacy assessments both before and after drugs enter clinical trials. ...

ByVeriSIM Life


The Five Factors of Smart Laboratory Success

The Five Factors of Smart Laboratory Success

Experience: Find your carrots Biologists in a global pharmaceuticals company were capturing and managing preclinical in vivo data with ad-hoc and Excel-based approaches. They were comfortable with this approach, but this made this critical data hard to find, hard to understand and hard to reuse by the modellers who wanted to introduce better ...

ByTessella Support Services plc

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT